Srihari S. Naidu, MD, is an interventional cardiologist whose areas of expertise include atrial septal defect (ASD) and patent foramen ovale (PFO) closure, alcohol septal ablation for hypertrophic obstructive cardiomyopathy, aortic and mitral valvuloplasty, percutaneous ventricular assist devices, and peripheral and coronary intervention including angioplasty and stent placement.  He is Board Certified in Internal Medicine, Cardiovascular Disease and Interventional Cardiology, and is a Tenured Associate Professor of Medicine at SUNY - Stony Brook School of Medicine.

Prior to joining Winthrop University Hospital in 2006, Dr. Naidu was an Assistant Professor of Medicine in the Division of Cardiology at New York Presbyterian Hospital - Weill Cornell Medical Center, where he was the second highest volume interventional cardiologist.  Dr. Naidu developed the Hypertrophic Cardiomyopathy Treatment Center at Cornell, performing their first series of alcohol septal ablations.  Dr. Naidu trained in Internal Medicine at Cornell, and General Cardiology and Interventional Cardiology at the University of Pennsylvania Medical Center.  A graduate of the 8-year Program in Liberal Medical Education at Brown University, Dr. Naidu remains active at Brown University as the President of the Brown Medical School Board of Directors, and Co-President of the Brown University Undergraduate Class of 1993 (www.brown.edu/academics/medical/gateway/alumni/brown-medical-alumni-association/board-of-directors).  Most recently, he was elected to Trustee of Brown University in 2013.

Under Dr. Naidu's leadership, the Cardiac Catheterization Laboratory at Winthrop University Hospital has grown in procedural volume, breadth of procedures, and regional and national reputation, while maintaining the highest quality of patient outcomes.  Significantly, the lab has developed a track record for bringing the latest technologies and techniques to Long Island before other hospitals, including the first implantation of Xience and Endeavor drug-eluting stents, the first Impella ventricular assist device for high-risk angioplasty, and one of the highest volume centers using minimially-invasive techniques to replace heart valves (TAVR).  In addition, Dr. Naidu and his team perform more ASD/PFO closures and alcohol septal ablations, with a proven track record of high quality and success, than any other adult interventional cardiologist on Long Island.

A Fellow of the American College of Cardiology (FACC), American Heart Association (FAHA), Society for Cardiovascular Angiography and Interventions (FSCAI) and American College of Chest Physicians (FCCP), Dr. Naidu serves on several prestigious national committees, including the ACC Interventional Science Council (two term member) and TCT Scientific Committee.  In addition, Dr. Naidu Founded and Chairs the Emerging Leader Mentorship (ELM) Program run by SCAI in partnership with ACC and the Cardiovascular Research Foundation (CRF), a dedicated interventional leadership pipeline that selects and mentors 10 interventional cardiologists every 2 years for national roles.  More information on the ELM Program may be found at www.scai.org/ELM.  For his leadership work within SCAI, he was elected Trustee of the Society (www.scai.org/About/Trustees.aspx) in 2011.

Dr. Naidu has published over 100 original articles, book chapters and abstracts dealing with angioplasty outcomes, new technology and innovative procedural modifications, and regularly lectures throughout the United States and Europe.  He is currently editing a textbook on Hypertrophic Cardiomyopathy through Springer Publishing in the United Kingdom.  In addition, he routinely serves as Invited Speaker for the American College of Cardiology (ACC), American Heart Association (AHA), Transcatheter Cardiovascular Therapeutics (TCT), and Society for Cardiac Angiography and Intervention (SCAI) Scientific Sessions.